Discover
CDXS
Codexis, Inc.
2.39
2 x 1.70
2 x 2.81
bid
ask
+
0.13
5.75%
2 @ 04:00 PM
2.39 +0.00 (0.00%)
| Ytd | 46.63% | |
| 1y | -0.42% |
2.17
day range
2.40
0.96
52 week range
3.87
| Open | 2.27 | Prev Close | 2.26 | Low | 2.17 | High | 2.40 | Mkt Cap | 217.24M |
| Vol | 1.03M | Avg Vol | 1.13M | EPS | -0.35 | P/E | N/A | Forward P/E | -7.14 |
| Beta | 2.07 | Short Ratio | 2.56 | Inst. Own | 79.79% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 2.55 | 200-d Avg | 2.02 | 1yr Est | 7.17 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-10-31 | 2024-09 | -0.25 | -0.29 | -0.04 | -16.00% |
| 2024-08-08 | 2024-06 | -0.26 | -0.32 | -0.06 | -23.08% |
| 2024-05-02 | 2024-03 | -0.17 | -0.16 | 0.01 | 5.88% |
| 2024-02-28 | 2023-12 | -0.16 | 0.02 | 0.18 | 112.50% |
| 2023-11-02 | 2023-09 | -0.32 | -0.26 | 0.06 | 18.75% |
| 2023-08-03 | 2023-06 | -0.21 | -0.17 | 0.04 | 19.05% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-22 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
| 2024-11-15 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
| 2024-11-04 | Benchmark | Upgrade | Hold | |
| 2024-09-20 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
| 2024-08-29 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
| 2024-08-19 | Benchmark | Downgrade | Buy | Hold |
Profile
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-11-06 | DE VRE RAYMOND | Director | 47.85K | Stock Award(Grant) |
| 2024-06-10 | DORGAN BYRON L | Director | 223.58K | Stock Award(Grant) |
| 2024-10-09 | ERBEZ GEORGIA L | Chief Financial Officer | 50.00K | Stock Award(Grant) |
| 2024-06-10 | MARTINBOROUGH ESTHER | Director | 88.05K | Stock Award(Grant) |
| 2024-10-09 | MOORE ALISON | Chief Technology Officer | 148.70K | Stock Award(Grant) |
| 2024-10-24 | OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Opaleye Management Inc. | 8.77M | 43.24M | 10.78% |
| 2024-09-29 | Casdin Capital, LLC | 8.10M | 39.93M | 9.95% |
| 2024-09-29 | Blackrock Inc. | 6.92M | 34.09M | 8.50% |
| 2024-09-29 | FMR, LLC | 4.50M | 22.17M | 5.53% |
| 2024-09-29 | Vanguard Group Inc | 4.15M | 20.47M | 5.10% |
| 2024-09-29 | Nantahala Capital Management, LLC | 2.97M | 14.63M | 3.65% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 2.08M | 10.23M | 2.55% |
| 2024-10-30 | iShares Russell 2000 ETF | 1.81M | 8.93M | 2.23% |
| 2024-07-30 | Columbia Fds Ser Tr I-Columbia Small Cap Value Fd I | 1.27M | 6.25M | 1.56% |
| 2024-10-30 | Variable Insurance Products Fund-Growth Portfolio | 1.14M | 5.63M | 1.40% |
| 2024-10-30 | Fidelity Advisor Equity Growth Fund | 1.12M | 5.54M | 1.38% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 1.02M | 5.01M | 1.25% |